EHNA
Based on 5 publication(s) in Google Scholar
EHNA is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects.
For research use only. We do not sell to patients.
- CAS No.: 51350-19-7
- Formula: C14H23N5O
- Molecular Weight:277.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) EHNA
More
Biological Activity
Chemical Information
-
CAS No. 51350-19-7
-
Molecular Weight 277.37
-
Formula C14H23N5O
-
SMILES
CCCCCC[C@@](N1C2=C(C(N)=NC=N2)N=C1)([H])[C@H](O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
Metabolic isotopic labeling of (deoxy)ribose enables dual neutral loss scanning for profiling nucleic acid modifications. [Abstract]2026 Feb 24;54(5):gkag155. PMID: 41732913 -
Front Immunol
CD38+CD39+ NK cells associate with HIV disease progression and negatively regulate T cell proliferation. [Abstract]2022 Oct 4:13:946871. PMID: 36268017 -
Oncoimmunology
Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles. [Abstract]2022 Dec 26;12(1):2152635. PMID: 36605619 -
Eur J Pharmacol
Bay 60-7550, a PDE2 inhibitor, exerts positive inotropic effect of rat heart by increasing PKA-mediated phosphorylation of phospholamban. [Abstract]2021 Jun 15:901:174077. PMID: 33798601 -
Biomed Chromatogr
Distribution and Pharmacokinetic Characteristics of Cordycepin in Rat: Investigated by UHPLC-HRMS/MS and Blood-Brain Synchronous Microdialysis. [Abstract]2025 Apr;39(4):e70038. PMID: 40071940
Purity & Documentation
References
[1]. Podzuweit T, et al. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine.Cell Signal. 1995 Sep;7(7):733-8. [Content Brief]
[2]. Michie AM, et al. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.Cell Signal. 1996 Feb;8(2):97-110. [Content Brief]
[3]. Blázquez-Bermejo C, et al. Increased dNTP pools rescue mtDNA depletion in human POLG-deficient fibroblasts. FASEB J. 2019 Jun;33(6):7168-7179. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
EHNA Related Classifications
HY-103160B Related Classifications
Powered by Bioz